亚甲基二磷酸盐联合氯化锶治疗多发性骨转移癌骨痛的效果观察  

Effect of methylene diphosphate combined with strontium chloride in the treatment of bone pain caused by multiple bone metastases

作　　者：刘建国 刘晓利 康进军[1] 张旭 Liu Jianguo;Liu Xiaoli;Kang Jinjun;Zhang Xu(Department of Nuclear Medicine,the General Hospital of Datong Coal Group,Datong,Shanxi 037003,China)

机构地区：[1]大同同煤集团总医院核医学科,山西省037003

出　　处：《中国基层医药》2020年第7期855-858,共4页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的:探讨亚甲基二磷酸盐(99TC-MDP,云克)联合氯化锶( 89SrCl 2)治疗多发性骨转移癌骨痛的临床疗效。 方法:回顾性分析大同同煤集团总医院2014年8月至2019年7月收治的多发性骨转移癌骨痛患者95例的临床资料,依据治疗方法不同分为三组,云克组37例采用单独云克治疗、 89SrCl 2组29例采用单独 89SrCl 2治疗,联合组29例采用云克联合 89SrCl 2治疗,三组均治疗5 d,每月为1疗程。比较三组临床疗效、止痛时间及不良反应。 结果:治疗后,云克组、 89SrCl 2组、联合组患者疼痛缓解率分别为67.6%(25/37)、69.0%(20/29)、79.3%(23/29),联合组疼痛缓解率高于云克组(χ 2=4.25, P<0.05);联合组骨转移灶有效率为41.4%(12/29),高于云克组的0.0%(0/37)、 89SrCl 2组的17.2%(5/29),差异均有统计学意义(χ 2=13.09、10.54,均 P<0.01)。三组均未发现严重不良反应。 结论:云克联合 89SrCl 2治疗骨转移癌,明显优于单独 89SrCl 2及单独云克治疗,且安全。Objective To investigate the clinical efficacy of Yunke(99TC-MDP)combined with strontium 89SrCl2 in the treatment of bone pain in patients with multiple bone metastases.Methods The clinical data of 95 patients with multiple bone metastases admitted to the General Hospital of Datong Coal Group from August 2014 to July 2019 were retrospectively analyzed.According to the different treatment methods,they were divided into three groups:37 patients in Yunke group were treated with Yunke alone,29 patients in 89SrCl2 group were treated with 89SrCl2 alone,29 patients in combination group were treated with Yunke combined with 89SrCl2.All patients were treated for 5 days,with a course of treatment per month.The clinical efficacy,analgesic time and adverse reactions of the three groups were compared.Results After treatment,the pain relief rates of the Yunke group,the 89SrCl2 group and the combination group were 67.6%(25/37),69.0%(20/29)and 79.3%(23/29),respectively.The pain relief rate of the combined group was higher than that of the Yunke group(χ2=4.25,P<0.05).The effective rate of bone metastases in the combined group was 41.4%(12/29),which was higher than that in the Yunke group[0.0%(0/37)],the 89SrCl2 group[17.2%(5/29)],the differences were statistically significant(χ2=13.09,10.54,all P<0.01).No serious adverse reactions were found in the three groups.Conclusion Yunke combined with 89SrCl2 is superior to 89SrCl2 alone,and it is safe in the treatment of bone metastases.

关 键 词：肿瘤转移 骨转移癌 骨痛 亚甲基二磷酸盐 氯化锶 对比研究 

分 类 号：R73[医药卫生—肿瘤]